Select a medication above to begin.
Wezlana (ustekinumab-auub)
ustekinumab
Adult Dosing .
Dosage forms: INJ (ConfiPen SC auto-injector): 45 mg, 90 mg; INJ (SC pre-filled syringe): 45 mg per 0.5 mL, 90 mg per mL; INJ (SC vial): 45 mg per 0.5 mL; INJ (IV vial): various
Special Note
- [drug name clarification]
- Info: nonproprietary name = ustekinumab-auub
psoriasis, moderate-severe plaque
- [<100 kg]
- Dose: 45 mg SC q12wk; Start: 45 mg SC x1 on wk 0, 4, then q12wk
- [>100 kg]
- Dose: 90 mg SC q12wk; Start: 90 mg SC x1 on wk 0, 4, then q12wk; Info: may decr. dose to 45 mg if full dose intolerable
psoriatic arthritis
- [45 mg SC q12wk]
- Start: 45 mg SC x1 on wk 0, 4, then q12wk; Info: give 90 mg SC x1 on wk 0, 4, then q12wk if >100 kg with coexisting plaque psoriasis
Crohn disease, moderate-severe
- [induction tx, <55kg]
- Dose: 260 mg IV x1
- [induction tx, 55-85kg]
- Dose: 390 mg IV x1
- [induction tx, >85kg]
- Dose: 520 mg IV x1
- [maintenance tx]
- Dose: 90 mg SC q8wk; Start: 8wk after induction dose
ulcerative colitis, moderate-severe
- [induction tx, <55kg]
- Dose: 260 mg IV x1
- [induction tx, 55-85kg]
- Dose: 390 mg IV x1
- [induction tx, >85kg]
- Dose: 520 mg IV x1
- [maintenance tx]
- Dose: 90 mg SC q8wk; Start: 8wk after induction dose
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (ConfiPen SC auto-injector): 45 mg, 90 mg; INJ (SC pre-filled syringe): 45 mg per 0.5 mL, 90 mg per mL; INJ (SC vial): 45 mg per 0.5 mL; INJ (IV vial): various
Special Note
- [drug name clarification]
- Info: nonproprietary name = ustekinumab-auub
psoriasis, moderate-severe plaque
- [6 yo and older, <60 kg]
- Dose: 0.75 mg/kg/dose SC q12wk; Start: 0.75 mg/kg/dose SC x1 on wk 0, 4, then q12wk
- [6 yo and older, 60-100 kg]
- Dose: 45 mg SC q12wk; Start: 45 mg SC x1 on wk 0, 4, then q12wk
- [6 yo and older, >100 kg]
- Dose: 90 mg SC q12wk; Start: 90 mg SC x1 on wk 0, 4, then q12wk
psoriatic arthritis
- [6 yo and older, <60 kg]
- Dose: 0.75 mg/kg/dose SC q12wk; Start: 0.75 mg/kg/dose SC x1 on wk 0, 4, then q12wk
- [6 yo and older, >60 kg]
- Dose: 45 mg SC q12wk; Start: 45 mg SC x1 on wk 0, 4, then q12wk; Info: give 90 mg SC x1 on wk 0, 4, then q12wk if >100 kg with coexisting plaque psoriasis
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- TB infection, active
- caution: patients >60 yo
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection risk
- caution: TB infection, latent
- caution: TB infection risk
- caution: malignancy
- caution: malignancy history
- caution: malignancy risk
- caution: PUVA tx
- caution: PUVA tx history
- caution: immunosuppressant use, prolonged
- caution: allergen immunotherapy use, concurrent
- caution: allergen immunotherapy use history
Drug Interactions .
Overview
ustekinumab
IL-12/IL-23 antagonist
- immunomodulatory effects
- caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abrocitinib
- adalimumab
- anifrolumab
- cladribine oral
- deuruxolitinib
- etrasimod
- golimumab
- infliximab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- ritlecitinib
- ruxolitinib topical
- tofacitinib
- upadacitinib
Monitor/Modify Tx
- anthrax vaccine
- carfilzomib
- chikungunya vaccine
- COVID-19 vaccine
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- ebola vaccine, live
- everolimus
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- influenza H5N1 vaccine
- influenza vaccine
- Japanese encephalitis vaccine
- meningococcal vaccine
- mitomycin
- pneumococcal vaccine
- poliovirus vaccine
- respiratory syncytial virus vaccine
- sipuleucel-T
- smallpox/mpox vaccine, live
- tick-borne encephalitis vaccine
- typhoid vaccine
Caution Advised
- abatacept
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- carboplatin
- carmustine
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- coccidioides immitis skin test antigen
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- daunorubicin
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- doxorubicin
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etuvetidigene autotemcel
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- icotrokinra
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitoxantrone
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- narsoplimab
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rilonacept
- rilzabrutinib
- risankizumab
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- sibeprenlimab
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tocilizumab
- topotecan
- trabectedin
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- vamorolone
- vedolizumab
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, severe
- infection exacerbation
- infection reactivation
- malignancy
- hypersensitivity reaction, serious
- anaphylaxis
- angioedema
- hypersensitivity vasculitis
- posterior reversible encephalopathy syndrome
- pneumonia, interstitial
- pneumonia, eosinophilic
- pneumonia, cryptogenic organizing
Common Reactions
- infection
- URI
- headache
- abdominal pain
- injection site erythema
- diarrhea
- pruritus
- fatigue
- vomiting
- arthralgia
- nausea
- back pain
- dizziness
- pharyngolaryngeal pain
Safety/Monitoring .
Monitoring Parameters
TB test at baseline, then active TB signs/symptoms during and after tx D/C; dermatologic exams
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; risk of fetal harm not expected based on human data; no known risk of teratogenicity based on animal data at >100x MRHD; for infants exposed to ustekinumab in utero, weigh risk/benefit before administering live vaccines
Lactation
Clinical Summary
may use while breastfeeding; no known risk of infant harm based on limited human data and drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for ustekinumab: unknown; CYP450: unknown
Excretion: for ustekinumab: unknown; Half-life: 14.9-45.6 days (plaque psoriasis use), 19 days (Crohn disease or ulcerative colitis use)
Subclass: Inflammatory Bowel Disease (IBD) ; Interleukin-12/23 (IL-12/23) Antagonists ; Psoriasis, Systemic Agents ; Spondyloarthropathies
Mechanism of Action
for ustekinumab: binds to and interferes with interleukin-12 and interleukin-23 cytokines, reducing inflammation and altering immune response (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.